A Phase 3 interventional study of Denosumab and Placebo for risendronate in Steroid-induced Osteopor, Glucocorticoid-induced Ostepor, sponsored by Amgen. Completed at 99 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-27.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men and women 18 years of age or older who have been taking treatment. Men and women who are less than 50 years of age must have had a fracture as an adult to be eligible. Men and women who are 50 years of age or older who have been taking glucocorticoids must meet protocol-specific BMD criteria.
Exclusion Criteria:
Use of agents affecting bone metabolism, use of more than one biologic agent for inflammatory disease, history of bone disease (except osteoporosis), low vitamin D level (one can enter the trial after vitamin D levels are corrected), abnormalities of blood calcium, an underactive or overactive thyroid condition that is not treated and stable, Addison's disease, any abnormality of the parathyroid glands (the glands that control blood calcium), currently pregnant or planning a pregnancy, currently breast feeding, and other criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
Drug: Denosumab · Drug: Placebo for risendronate
Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
Drug: Risendronate · Drug: Placebo for denosumab
Administered by subcutaneous injection once every 6 months
Also known as: Prolia®
Administered orally once a day
Administered orally once a day
Also known as: Actonel, Atelvia
Administered by subcutaneous injection once every 6 months
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis)
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
Time frame: Baseline and month 12
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Superiority Analysis)
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
Time frame: Baseline and month 12
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA).
Time frame: Baseline and month 12
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 24
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
Time frame: Baseline and month 24
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 24
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA).
Time frame: Baseline and month 24
Participants were enrolled at 79 centers in Europe, North America, Latin America, and Korea from 28 March 2012 to 30 June 2015. Participants who had been taking glucocorticoids for at least 3 months were classed as glucocorticoid continuing; those who were taking glucocorticoids for less than 3 months were classed as glucocorticoid initiating.
| Milestone | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing |
|---|---|---|---|---|
| Started | 145 | 145 | 252 | 253 |
| Received study drug | 140 | 142 | 246 | 251 |
| Completed | 117 | 109 | 178 | 186 |
| Not completed | 28 | 36 | 74 | 67 |
| Withdrew: Withdrawal by subject | 15 | 20 | 34 | 34 |
| Withdrew: Adverse event | 7 | 7 | 9 | 12 |
| Withdrew: Lost to follow-up | 1 | 3 | 13 | 5 |
| Withdrew: Death | 3 | 2 | 8 | 9 |
| Withdrew: Noncompliance | 1 | 2 | 4 | 3 |
| Withdrew: Administrative decision | 1 | 1 | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 1 |
| Withdrew: Requirement for alternative therapy | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 4 | 2 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
| percent change | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing |
|---|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) | 0.8 (0.2 to 1.5) | 3.8 (3.1 to 4.5) | 2.3 (1.7 to 2.9) | 4.4 (3.8 to 5.0) |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
| percent change | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing |
|---|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Superiority Analysis) | 0.8 (0.2 to 1.5) | 3.8 (3.1 to 4.5) | 2.3 (1.7 to 2.9) | 4.4 (3.8 to 5.0) |
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA).
| percent change | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing |
|---|---|---|---|---|
| Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12 | 0.2 (-0.2 to 0.7) | 1.7 (1.2 to 2.2) | 0.6 (0.2 to 1.0) | 2.1 (1.7 to 2.5) |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).
| percent change | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing |
|---|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 24 | 1.7 (0.8 to 2.7) | 6.2 (5.3 to 7.2) | 3.2 (2.3 to 4.1) | 6.4 (5.5 to 7.2) |
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA).
| percent change | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing |
|---|---|---|---|---|
| Percent Change From Baseline in Total Hip Bone Mineral Density at Month 24 | -0.0 (-0.6 to 0.6) | 3.1 (2.4 to 3.7) | 0.5 (-0.1 to 1.0) | 2.9 (2.4 to 3.5) |
Collected over 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risedronate | 9/385 (2.3%) | 98/385 (25.5%) | 76/385 (19.7%) |
| Denosumab | 13/394 (3.3%) | 92/394 (23.4%) | 77/394 (19.5%) |
| Event | Risedronate | Denosumab |
|---|---|---|
| PneumoniaInfections and infestations | 8/385 | 7/394 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/385 | 2/394 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/385 | 0/394 |
| Back painMusculoskeletal and connective tissue disorders | 3/385 | 1/394 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/385 | 1/394 |
| Cardiac failureCardiac disorders | 0/385 | 3/394 |
| Femur fractureInjury, poisoning and procedural complications | 0/385 | 3/394 |
| Cerebrovascular accidentNervous system disorders | 1/385 | 3/394 |
| Transient ischaemic attackNervous system disorders | 1/385 | 3/394 |
| AnaemiaBlood and lymphatic system disorders | 2/385 | 1/394 |
| Event | Risedronate | Denosumab |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 33/385 | 23/394 |
| Back painMusculoskeletal and connective tissue disorders | 21/385 | 24/394 |
| HypertensionVascular disorders | 15/385 | 21/394 |
| Viral upper respiratory tract infectionInfections and infestations | 19/385 | 20/394 |
| Age, Continuous(years) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| Mean | 64.4 ± 10.0 | 67.5 ± 10.1 | 61.3 ± 11.1 | 61.5 ± 11.6 | 63.1 ± 11.1 |
| Age, Customized(Participants) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| < 50 years | 5 | 2 | 26 | 33 | 66 |
| 50 - 64 years | 75 | 55 | 130 | 114 | 374 |
| 65 - 74 years | 38 | 50 | 62 | 73 | 223 |
| ≥ 75 years | 27 | 38 | 34 | 33 | 132 |
| Sex: Female, Male(Participants) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| Female | 93 | 93 | 185 | 185 | 556 |
| Male | 52 | 52 | 67 | 68 | 239 |
| Ethnicity (NIH/OMB)(Participants) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 20 | 54 | 43 | 135 |
| Not Hispanic or Latino | 127 | 125 | 198 | 210 | 660 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| White | 123 | 122 | 223 | 230 | 698 |
| Other | 11 | 12 | 11 | 13 | 47 |
| Asian | 9 | 9 | 12 | 6 | 36 |
| Black or African American | 2 | 2 | 4 | 4 | 12 |
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Multiple | 0 | 0 | 1 | 0 | 1 |
| Menopausal Status(Participants) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| Premenopause | 7 | 10 | 25 | 24 | 66 |
| Postmenopause | 83 | 82 | 157 | 159 | 481 |
| Unknown | 3 | 1 | 3 | 2 | 9 |
| Lumbar Spine Bone Mineral Density (BMD) T-score(T-score) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| Glucocorticoid-initiating Subpopulation | -1.06 ± 1.57 | -0.92 ± 1.86 | — | — | -0.99 ± 1.72 |
| Glucocorticoid-continuing Subpopulation | — | — | -1.96 ± 1.38 | -1.92 ± 1.38 | -1.94 ± 1.38 |
| Total Hip BMD T-score(T-score) | Risedronate: Glucocorticoid-initiating | Denosumab: Glucocorticoid-initiating | Risedronate: Glucocorticoid-continuing | Denosumab: Glucocorticoid-continuing | Total |
|---|---|---|---|---|---|
| Glucocorticoid-initiating Subpopulation | -0.98 ± 1.07 | -1.14 ± 1.00 | — | — | -1.06 ± 1.04 |
| Glucocorticoid-continuing Subpopulation | — | — | -1.56 ± 0.96 | -1.66 ± 0.96 | -1.61 ± 0.96 |
Ran from Mar 2012 to primary completion in Jun 2016, 50 months.
Results were first posted in Jul 2018, 2 years 1 month after primary completion. A results delay was requested in May 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab